Gail M, Beach J, Dark A, Lewis R, Morrow H
J Chronic Dis. 1982 Feb;35(2):151-61. doi: 10.1016/0021-9681(82)90115-1.
Seventy-nine homozygous SS patients were randomly assigned to control or oral prophylactic urea treatment in a double-blind trial designed to determine whether prophylactic oral urea, in low doses, prevents sickle cell crises. The average follow-up time for these patients was 13.7 months and 33 patients were diagnosed as having one or more crises during the study. No statistically significant treatment differences were found in weight changes, bilirubin changes, or hemoglobin changes over the course of the study or in the distribution of time to first crises or time to second crisis. This study gives no evidence in favor of the hypothesis that prophylactic oral urea, in low doses, prolongs time to crisis.
在一项旨在确定低剂量口服预防性尿素是否能预防镰状细胞危象的双盲试验中,79名纯合子SS患者被随机分配接受对照治疗或口服预防性尿素治疗。这些患者的平均随访时间为13.7个月,33名患者在研究期间被诊断出发生一次或多次危象。在研究过程中的体重变化、胆红素变化或血红蛋白变化,以及首次危象发生时间或第二次危象发生时间的分布方面,未发现治疗差异有统计学意义。这项研究没有提供证据支持低剂量口服预防性尿素能延长危象发生时间这一假设。